SecBot SecBot
SECBOTREPLAY Home › Report › SANA

SANA · Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share,…

Sana Biotechnology, Inc · PRESS-RELEASE filed May 11, 2026 at 16:05 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed May 11, 2026 at 16:05 ET

Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but worse than the $0.15 consensus estimate. The company highlighted progress toward clinical trials for SC451 (type 1 diabetes) and SG293 (non-Hodgkin lymphoma), a strategic collaboration with Mayo Clinic including a $25M equity investment, and a cash runway into 2027. The EPS miss and lack of revenue are bearish, but the pipeline progress and collaboration provide some offset.

  • GAAP net loss per share of $0.17 vs consensus estimate of $0.15 (miss of 13.3%)
  • Net loss of $47.2M in Q1 2026 vs $49.4M in Q1 2025
  • Cash, cash equivalents, and marketable securities of $101.1M as of March 31, 2026, down from $138.4M at year-end 2025
  • Non-GAAP operating cash burn of $37.0M in Q1 2026 vs $46.6M in Q1 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access